NovoCure (NVCR) Invested Capital (2014 - 2026)

NovoCure's Invested Capital history runs 13 years deep, the most recent figure standing at $330.7 million for Q1 2026.

• In Q1 2026, Invested Capital fell 8.63% year-over-year to $330.7 million; the TTM figure through Mar 2026 stood at $330.7 million (down 8.63% YoY), while the FY2025 annual figure was $340.5 million, down 5.47% from the prior year.
• Invested Capital came in at $330.7 million for Q1 2026 at NovoCure, down from $340.5 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $1.0 billion in Q3 2022 to a low of $330.7 million in Q1 2026.
• A 5-year average of $650.8 million and a median of $415.7 million in 2023 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital grew 7.21% in 2022 and sank 62.48% in 2024, its largest moves.
• NovoCure's Invested Capital stood at $1.0 billion in 2022, then dropped by 7.49% to $931.3 million in 2023, then tumbled by 61.33% to $360.2 million in 2024, then dropped by 5.47% to $340.5 million in 2025, then fell by 2.86% to $330.7 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $330.7 million, $340.5 million, and $341.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison